The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
- Order Number
- Package Size
- 100 µl
The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).
A minimally deleted region on chromosome 4q24 is described in subgroups of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). The region encompasses the TET2 gene. The frequency of TET2 mutations in unselected patients was 19 % (15 of 81 patients) with myelodysplastic syndromes, 12 % (24 of 198 patients) with myeloproliferative disorders, 24 % (5 of 21 patients) with secondary AML, and 22 % (2 of 9 patients) with chronic myelomonocytic leukemia.
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)
- Chronic Myelogenous Leukemia (CML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating a deletion of TET2 (4q24).
- Jankowska et al (2009) Blood 113:6403-6410
- Delhommeau et al (2009) N Engl J Med 360:2289-2301
- Flach et al (2010) Haematologica 95:518-519